Please Wait.....
Report
South America Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type (9-valent HPV Vaccine, Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose), Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and Genital Warts), and End User (Doctors Office, Community Health Clinics, School-Based Health Centers, Health Departments, Hospitals, and Others)
Market Report I 2022-09-26 I 134 Pages I The Insight Partners
The South America human papillomavirus (HPV) vaccine market is expected to grow from US$ 173.52 million in 2022 to US$ 239.53 million by 2028; it is estimated to grow at a CAGR of 5.5% from 2022 to 2028.
Companies are undertaking many research and development activities to introduce advanced HPV tests. For instance, in May 2021, BD, a leading medical technology company, launched the first CE-marked assay for HPV screening from at-home self-collected vaginal samples. This allows laboratories to process self-collected samples via a BD diluent tube. At-home collection of samples will help address the urgent public health challenge of reaching out to women who do not attend routine cervical cancer screening. Further, in September 2020, drug administrations across the region approved the expanded use of F. Hoffmann-La Roche Ltd, CINtec PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). The CINtec PLUS Cytology test identifies the simultaneous presence of the two biomarkers-p16 and Ki-67-in a single cell. This abnormality is associated with HPV infections that progress to pre-cancer or cancer if not treated. A positive result of these two biomarkers means the person taking the test is at a high risk of getting the disease. Such robust developments in HPV diagnostics tests are likely to reshape the market during the forecast period.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the South America human papillomavirus (HPV) vaccine market . The South America human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.
South America Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
South America Human Papillomavirus (HPV) Vaccine Market Segmentation
The South America human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country. Based on type, the South America human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment would dominate the market in 2022. In terms of dosage, the South America human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment would dominate the market in 2022. Based on age, the South America human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment would dominate the market in 2022. In terms of application, the South America human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment would dominate the market in 2022. Based on end user, the South America human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment would dominate the market in 2022. Based on country, the South America human papillomavirus (HPV) vaccine market has been categorized into Brazil, Argentina, Chile, Guatemala, Peru, Colombia, and the Rest of South America. Brazil would dominate the market in 2022.
GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; and Serum Institute of India Pvt. Ltd are among the leading companies in the South America human papillomavirus (HPV) vaccine market.
TABLE OF CONTENTS
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 SAM Human Papillomavirus (HPV) Vaccines Market - By Type
1.3.2 SAM Human Papillomavirus (HPV) Vaccines Market - By Dosage
1.3.3 SAM Human Papillomavirus (HPV) Vaccines Market - By Age
1.3.4 SAM Human Papillomavirus (HPV) Vaccines Market - By Application
1.3.5 SAM Human Papillomavirus (HPV) Vaccines Market - By Distribution Channel
1.3.6 SAM Human Papillomavirus (HPV) Vaccines Market - By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. SAM Human Papillomavirus (HPV) Vaccine Market - Market Landscape
4.1 Overview
4.2 SAM PEST Analysis
4.3 Experts Opinion
5. SAM Human Papillomavirus (HPV) Vaccine Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Prevalence of HPV Associated Diseases
5.1.2 Initiatives Taken by Health Organizations
5.2 Market Restraints
5.2.1 High Cost of HPV Vaccines
5.3 Future Trends
5.3.1 Advancements in HPV Diagnostics Tests
5.4 Impact Analysis
6. Human Papillomavirus (HPV) Vaccine Market - SAM Analysis
6.1 SAM Human Papillomavirus (HPV) Vaccine Market Revenue Forecast and Analysis
7. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By Type
7.1 Overview
7.2 By Type: Market Revenue and Forecast Analysis (US$ Million)
7.3 9-valent HPV vaccine
7.3.1 Overview
7.3.2 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
7.4 Quadrivalent HPV vaccine
7.4.1 Overview
7.4.2 Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
7.5 Bivalent HPV Vaccine
7.5.1 Overview
7.5.2 Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)
8. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By Dosage
8.1 SAM Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)
8.2 2 Dose
8.2.1 Overview
8.2.2 2 Dose: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
8.3 3 Dose
8.3.1 Overview
8.3.2 3 Dose: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
9. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By Age
9.1 SAM Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)
9.2 9 to 14 Years
9.2.1 Overview
9.2.2 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
9.3 to 45 Years
9.3.1 Overview
9.3.2 to 45 Years: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
10. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By Application
10.1 SAM Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)
10.2 HPV-attributable Cancer
10.2.1 Overview
10.2.2 HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
10.3 Genital Warts
10.3.1 Overview
10.3.2 Genital Warts: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
11. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By End User
11.1 Overview
11.2 SAM Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)
11.3 Doctor Office
11.3.1 Overview
11.3.2 Doctor Office Market Revenue and Forecast to 2028 (US$ Million)
11.4 Community Health Clinics
11.4.1 Overview
11.4.2 Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)
11.5 School-based Health Centers
11.5.1 Overview
11.5.2 School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)
11.6 Health Departments
11.6.1 Overview
11.6.2 Health Departments Market Revenue and Forecast to 2028 (US$ Million)
11.7 Hospitals
11.7.1 Overview
11.7.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)
11.8 Others
11.8.1 Overview
11.8.2 Others Market Revenue and Forecast to 2028 (US$ Million)
12. SAM Human Papillomavirus (HPV) Vaccine Market - Country Analysis
12.1 Overview
12.1.1 SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Country (%)
12.1.1.1 Argentina Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.1.1 Overview
12.1.1.1.2 Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.1.1.1.3 Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.1.1.1.4 Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.1.1.1.5 Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.1.1.1.6 Argentina: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.1.1.1.7 Argentina: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
12.1.1.2 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.2.1 Overview
12.1.1.2.2 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.1.1.2.3 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.1.1.2.4 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.1.1.2.5 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.1.1.2.6 Brazil: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.1.1.2.7 Brazil: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
12.1.1.3 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.3.1 Overview
12.1.1.3.2 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.1.1.3.3 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.1.1.3.4 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.1.1.3.5 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.1.1.3.6 Chile: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.1.1.3.7 Chile: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
12.1.1.4 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.4.1 Overview
12.1.1.4.2 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.1.1.4.3 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.1.1.4.4 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.1.1.4.5 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.1.1.4.6 Guatemala: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.1.1.4.7 Guatemala: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
12.1.1.5 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.5.1 Overview
12.1.1.5.2 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.1.1.5.3 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.1.1.5.4 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.1.1.5.5 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.1.1.5.6 Peru: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.1.1.5.7 Peru: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
12.1.1.6 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
12.1.1.6.1 Overview
12.1.1.6.2 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.1.1.6.3 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.1.1.6.4 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.1.1.6.5 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.1.1.6.6 Colombia: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.1.1.6.7 Colombia: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
12.1.1.7 Rest of South and Central America: Human Papillomavirus (HPV) Vaccine Market- Revenue and Forecast to 2028 (USD Million)
12.1.1.7.1 Overview
12.1.1.7.2 Rest of SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
12.1.1.7.3 Rest of SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
12.1.1.7.4 Rest of SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
12.1.1.7.5 Rest of SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
12.1.1.7.6 Rest of SAM: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.1.1.7.7 Rest of SAM: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
13. Industry Landscape
13.1 Overview
13.2 Inorganic Growth Strategies
13.2.1 Overview
13.3 Organic Growth Strategies
13.3.1 Overview
14. Company Profiles
14.1 Merck & Co., Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 GlaxoSmithKline plc.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Serum Institute of India Pvt. Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Inovio Pharmaceuticals
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Sanofi
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 R-Pharm
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. SAM Human Papillomavirus (HPV) Vaccine Market, Revenue and Forecast, 2019-2028 (US$ Mn)
Table 2. Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 3. Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 4. Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 5. Argentina: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 6. Argentina: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
Table 7. Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 8. Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 9. Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 10. Brazil: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 11. Brazil: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
Table 12. Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 13. Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 14. Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 15. Chile: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 16. Chile: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
Table 17. Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 18. Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 19. Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 20. Guatemala: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 21. Guatemala: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
Table 22. Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 23. Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 24. Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 25. Peru: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 26. Peru: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
Table 27. Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 28. Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 29. Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 30. Colombia: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 31. Colombia: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
Table 32. Rest of SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)
Table 33. Rest of SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)
Table 34. Rest of SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)
Table 35. Rest of SAM: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 36. Rest of SAM: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US$ Million)
Table 37. Recent Inorganic Growth Strategies
Table 38. Recent Organic Growth Strategies
Table 39. Glossary of Terms
LIST OF FIGURES
Figure 1. SAM Human Papillomavirus (HPV) Vaccines Market Segmentation
Figure 2. SAM Human Papillomavirus (HPV) Vaccines Market, By Country
Figure 3. SAM Human Papillomavirus (HPV) Vaccine Market Overview
Figure 4. SAM Human Papillomavirus (HPV) Vaccines Market, By Type
Figure 5. SAM Human Papillomavirus (HPV) Vaccines Market, By Country
Figure 6. SAM: PEST Analysis
Figure 7. Experts Opinion
Figure 8. SAM Human Papillomavirus (HPV) Vaccines Market Impact Analysis of Driver and Restraints
Figure 9. SAM Human Papillomavirus (HPV) Vaccine Market- Revenue Forecast and Analysis
Figure 10. By Type: Market Analysis and Forecast 2022 and 2028 (%)
Figure 11. SAM 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
Figure 12. SAM Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)
Figure 13. SAM Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)
Figure 14. SAM Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)
Figure 15. SAM 2 Dose: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
Figure 16. SAM 3 Dose: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
Figure 17. SAM Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)
Figure 18. SAM 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
Figure 19. SAM 15 to 45 Years: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
Figure 20. SAM Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)
Figure 21. SAM HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
Figure 22. SAM Genital Warts: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US$ Million)
Figure 23. SAM Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)
Figure 24. SAM Doctor Office Market Revenue and Forecast to 2028 (US$ Million)
Figure 25. SAM Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)
Figure 26. SAM School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)
Figure 27. SAM Health Departments Market Revenue and Forecast to 2028 (US$ Million)
Figure 28. SAM Hospitals Market Revenue and Forecast to 2028 (US$ Million)
Figure 29. SAM Others Market Revenue and Forecast to 2028 (US$ Million)
Figure 30. SAM Human Papillomavirus (HPV) Vaccine Market Overview, by Country (2022)
Figure 31. SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Country (%)
Figure 32. Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 33. Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 34. Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 35. Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 36. Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 37. Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
Figure 38. Rest of SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security